This is the authors' abstract. We don't add key points for this paper.
Bladder cancer is one of the most common urogenital malignant with a rising incidence rate all over the world. Non-muscle invasive bladder cancer (NMIBC) has the characteristics of high recurrence rate and easy progression after receiving transurethral tumor resection combined with intravesical chemotherapy. The intrinsic or/and acquired drug resistance is mainly causing this poor outcome. The continuing advances in metabolomics and single-cell mass spectrometry have been considered as the key to promoting clinical precision medicine. Urinary exfoliated tumor cells (UETCs) carry the first-hand biological information on the genesis and progression of primary bladder cancer. Therefore, we hypothesized that the establishment of a drug resistance monitoring system for bladder cancer with intravesical chemotherapy based on UETCs single-cell metabolomics technology has a broad application prospect.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Tian et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: